BCL2 and cholangiocarcinoma: Thus, in SNU-398 cells derived from HCC, Bcl-x(L) expression was induced during treatment with paclitaxel [66], whereas in CCA cells, Bcl2 upregulation, together with Bax downregulation, has been associated with resistance to 5-FU, cisplatin [67], and gemcitabine [68].